[Form 4] Cytosorbents Corp. Insider Trading Activity

Rhea-AI Filing Summary

Insider reported: Director Jiny Kim disclosed changes in beneficial ownership of Cytosorbents Corporation (CTSO). The Form 4 shows a reported disposition of 77,819 shares of Common Stock and an acquisition of 22,000 stock options with a $1 exercise price. The options were granted under the companys long-term incentive plan and will vest in four equal quarterly installments over one year following the grant, subject to continued service.

The 77,819 figure includes 69,300 RSUs that convert to shares only upon a defined change in control and 8,519 shares directly owned by the reporting person. The filing was signed by an attorney-in-fact and references a power of attorney exhibit.

Positive

• 22,000 stock options granted at a $1 exercise price, providing potential alignment with shareholders via time-based vesting
• 69,300 RSUs are structured to settle only upon a change in control, tying those awards to corporate transaction outcomes

Negative

• Disposition of 77,819 common shares by a director, which reduces the reporting person's direct shareholding
• Only 8,519 shares are indicated as currently owned outright by the reporting person, per the explanation

Insights

Corporate Governance Expert

TL;DR: Director reported a sizable disposal and received time-based option awards under the long-term incentive plan.

The filing documents a disposition of 77,819 common shares and a concurrent grant of 22,000 stock options at a $1 exercise price. Notably, 69,300 RSUs are subject to settlement only on a defined change in control, which preserves contingent alignment tied to a corporate transaction. The option vesting schedule is standard for retention awards (four equal quarterly installments over one year), and the disclosure includes an executed power of attorney. This pattern appears consistent with routine director compensation and equity rebalancing rather than an operational or governance red flag.

Securities Analyst

TL;DR: Transaction mixes a sale of existing shares with a compensation-focused option grant; materiality depends on company scale.

Facts in the form show a sale/disposition of 77,819 common shares and the acquisition of 22,000 options exercisable at $1, with options vesting quarterly over one year and an expiration consistent with a multi-year term. The disclosure clarifies the share count includes 69,300 RSUs that only convert on a change in control, which limits immediate dilution. From a market-impact perspective, the filing documents routine insider activity and equity compensation; the filing does not provide revenue or valuation context to assess materiality relative to company size.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Jiny

(Last) (First) (Middle)

C/O CYTOSORBENTS CORPORATION

305 COLLEGE ROAD EAST

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cytosorbents Corp [ CTSO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								77,819(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1	08/08/2025		A		22,000		(2)	08/08/2035	Common Stock	22,000	$0	22,000	D

Explanation of Responses:

1. Includes (a) 69,300 restricted stock units ("RSUs") granted on April 1, 2022 that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan") and (b) 8,519 shares of Common Stock owned by the reporting person.

2. The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

Remarks:

Exhibit 24.1 Power of Attorney

	/s/ Peter J. Mariani attorney-in-fact Jiny Kim	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the CTSO Form 4 filed by Director Jiny Kim report?

The form reports a disposition of 77,819 common shares and the acquisition of 22,000 stock options at a $1 exercise price.

How are the 22,000 stock options issued to the director structured?

The options were granted under the company's long-term incentive plan and vest in four equal quarterly installments over one year, subject to continued service.

What does the 77,819 shares figure include in the CTSO filing?

It includes 69,300 RSUs that will convert to shares only upon a defined change in control and 8,519 shares owned directly by the reporting person.

Does the form indicate indirect ownership or special arrangements?

The filing notes the RSUs and the option grant under the plan; it also references an exhibit Power of Attorney (Exhibit 24.1) for signature authority.

Are there exercisability or expiration dates listed for the options?

The options are recorded with an expiration consistent with a multi-year term and will vest over one year; the filing indicates an expiration date that aligns with the grant term in the table.